Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 14 | 5 | -0,21 % | ||
| INSMED | 12 | 7 | -0,25 % | ||
| NURIX THERAPEUTICS | 10 | 4 | -4,53 % | ||
| REGENERON PHARMACEUTICALS | 5 | 22 | -0,44 % | ||
| AMGEN | 4 | 27 | -0,08 % | ||
| NOVAVAX | 4 | 7 | -0,14 % | ||
| ANI PHARMACEUTICALS | 4 | 5 | -0,74 % | ||
| TERNS PHARMACEUTICALS | 4 | 2 | +0,64 % | ||
| BRIDGEBIO PHARMA | 4 | - | -0,66 % | ||
| ATAIBECKLEY | 4 | - | 0,00 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Centessa is the top performing foreign healthcare stock YTD | 2 | Seeking Alpha | ||
| Mi | Stifel reiterates Oruka Therapeutics stock rating ahead of trial data | 2 | Investing.com | ||
| Mi | RBC Capital startet Coverage für BridgeBio Pharma mit "Outperform" und Kursziel 100 US-Dollar | 1 | Investing.com Deutsch | ||
| Mi | RBC Capital initiates BridgeBio Pharma stock at Outperform with $100 target | 1 | Investing.com | ||
| Mi | Trial Failure in the Skin Does Not Dent Insmed Drug's Potential in the Lungs | 4 | MedCity News | ||
| Mi | Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake | 3 | Insider Monkey | ||
| Mi | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 | 1 | GlobeNewswire (USA) | ||
| Mi | Autolus Therapeutics plc - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | 3 | Benzinga.com | ||
| Mi | Why Terns Pharmaceuticals Stock Rocked the Market in March | 4 | The Motley Fool | ||
| Mi | Oppenheimer reiterates Nurix stock rating on trial progress | 1 | Investing.com | ||
| Mi | Oppenheimer bestätigt Nurix-Rating nach Fortschritten bei klinischer Studie | 2 | Investing.com Deutsch | ||
| Mi | Barclays: BridgeBio-Aktie bleibt "Overweight" - Attruby als Wachstumstreiber | 2 | Investing.com Deutsch | ||
| Mi | Stifel senkt Kursziel für Nurix auf 34 US-Dollar trotz Studienfortschritt | 3 | Investing.com Deutsch | ||
| Mi | Barclays reiterates Overweight on BridgeBio stock, cites Attruby strength | 3 | Investing.com | ||
| Mi | Stifel cuts Nurix stock price target to $34 on CLL trial progress | 1 | Investing.com | ||
| Mi | Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs 'expected' study failure | 40 | BioPharma Dive | ||
| Mi | Activist investor revives campaign to overhaul Novavax board | 4 | BioPharma Dive | ||
| Mi | With 3 quick buyouts, Gilead leans into its latest transformation | 4 | BioPharma Dive | ||
| Mi | Inhibrx gains as Stifel issues new Buy based on lead assets | 2 | Seeking Alpha |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.